Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Viktrup

Showing results (91-100 of 111) with videos related to

Pageof 12
Sort By:
JAMA|July 3, 2019
Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical TrialThomas J Schnitzer, Richard Easton, Shirley Pang, et al.
Surgical Technology International|May 27, 2021
Postoperative Outcome of Patients Who Underwent Total Joint Replacement During the Tanezumab Phase 3 Osteoarthritis Development Program: A 24-Week Observational StudyMichael A Mont, John A Carrino, Mary Anne Nemeth, et al.
Pain and Therapy|January 14, 2022
Satisfaction with Medications Prescribed for Osteoarthritis: A Cross-Sectional Survey of Patients and Their Physicians in the United StatesRebecca L Robinson, Thomas J Schnitzer, Sophie Barlow, et al.
BMC Neurology|March 13, 2025
Stigmatizing attitudes toward people with migraine by people without active migraine: results of the OVERCOME (US) studyRobert E Shapiro, Lars Viktrup, Eva Jolanda Muenzel, et al.
BMC Musculoskeletal Disorders|May 26, 2022
Factors associated with physician-reported treatment status of patients with osteoarthritis painThomas J Schnitzer, Rebecca L Robinson, Leslie Tive, et al.
Rheumatology and Therapy|October 4, 2021
Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with OsteoarthritisThomas J Schnitzer, Francis Berenbaum, Philip G Conaghan, et al.
European Journal of Pain (London, England)|December 2, 2021
Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysisDavid A Walsh, Marco Boeri, Lucy Abraham, et al.
Pain and Therapy|August 13, 2022
Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 TrialJohn D Markman, Thomas J Schnitzer, Serge Perrot, et al.
Pain Management|November 17, 2021
Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase III safety studyShin-Ichi Konno, Takuya Nikaido, John D Markman, et al.
Annals of the Rheumatic Diseases|April 3, 2020
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up periodFrancis Berenbaum, Francisco J Blanco, Ali Guermazi, et al.
Pageof 12

Showing results (91-100 of 111) with videos related to

Sort By:
Pageof 12
JAMA|July 3, 2019
Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical TrialThomas J Schnitzer, Richard Easton, Shirley Pang, et al.
Surgical Technology International|May 27, 2021
Postoperative Outcome of Patients Who Underwent Total Joint Replacement During the Tanezumab Phase 3 Osteoarthritis Development Program: A 24-Week Observational StudyMichael A Mont, John A Carrino, Mary Anne Nemeth, et al.
Pain and Therapy|January 14, 2022
Satisfaction with Medications Prescribed for Osteoarthritis: A Cross-Sectional Survey of Patients and Their Physicians in the United StatesRebecca L Robinson, Thomas J Schnitzer, Sophie Barlow, et al.
BMC Neurology|March 13, 2025
Stigmatizing attitudes toward people with migraine by people without active migraine: results of the OVERCOME (US) studyRobert E Shapiro, Lars Viktrup, Eva Jolanda Muenzel, et al.
BMC Musculoskeletal Disorders|May 26, 2022
Factors associated with physician-reported treatment status of patients with osteoarthritis painThomas J Schnitzer, Rebecca L Robinson, Leslie Tive, et al.
Rheumatology and Therapy|October 4, 2021
Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with OsteoarthritisThomas J Schnitzer, Francis Berenbaum, Philip G Conaghan, et al.
European Journal of Pain (London, England)|December 2, 2021
Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysisDavid A Walsh, Marco Boeri, Lucy Abraham, et al.
Pain and Therapy|August 13, 2022
Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 TrialJohn D Markman, Thomas J Schnitzer, Serge Perrot, et al.
Pain Management|November 17, 2021
Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase III safety studyShin-Ichi Konno, Takuya Nikaido, John D Markman, et al.
Annals of the Rheumatic Diseases|April 3, 2020
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up periodFrancis Berenbaum, Francisco J Blanco, Ali Guermazi, et al.
Pageof 12